Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc.
No insider data available
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|
Assets | |||||||
Assets Current | |||||||
Cash And Cash Equivalents At Carrying Value | 72 | 268 | |||||
Prepaid Expense Current | 5 | 3 | |||||
Other Assets Current | 6 | 0 | |||||
Assets Current | 275 | 286 | |||||
Restricted Cash Noncurrent | 0 | 0 | |||||
Property Plant And Equipment Net | 4 | 4 | |||||
Operating Lease Right Of Use Asset | 1 | 2 | |||||
Assets | 281 | 292 | |||||
Liabilities And Stockhold… | |||||||
Liabilities Current | |||||||
Accounts Payable Current | 4 | 1 | |||||
Accrued Liabilities Current | 13 | 7 | |||||
Operating Lease Liability Current | 2 | 3 | |||||
Contract With Customer Liability Current | 9 | 9 | |||||
Liabilities Current | 32 | 22 | |||||
Contract With Customer Liability Noncurrent | 34 | 36 | |||||
Other Liabilities Noncurrent | 1 | 0 | |||||
Liabilities | 66 | 58 | |||||
Stockholders Equity | |||||||
Common Stock Value | 0 | 0 | |||||
Additional Paid In Capital | 223 | 222 | |||||
Retained Earnings Accumulated Deficit | -8 | 12 | |||||
Stockholders Equity | 215 | 234 | |||||
Liabilities And Stockholders Equity | 281 | 292 | |||||
Common Stock Par Or Stated Value Per Share | 0.001 | 0.001 | |||||
Common Stock Shares Authorized | 400 | 400 | |||||
Common Stock Shares Issued | 17 | 17 | |||||
Shares Outstanding | 17 | 17 | |||||
Preferred Stock Par Or Stated Value Per Share | 0.001 | 0.001 | |||||
Preferred Stock Shares Authorized | 40 | 40 | |||||
Preferred Stock Shares Issued | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month |
|---|---|---|---|---|---|---|
| 2026 | -11.08% | 2.86% | -13.64% | - | - | - |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Atrium Therapeutics, Inc. (RNA) — SEC Financial Statements & Analysis
Atrium Therapeutics, Inc. (RNA) is a pharmaceutical preparations company, incorporated in DE. Atrium Therapeutics, Inc. trades on Nasdaq as: RNA. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Atrium Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.31x, a Price-to-Book (P/B) ratio of 1.07x (TTM), at a market cap of $230.08M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.31x
- P/B TTM
- 1.07x
- Market Cap
- $230.08M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Atrium Therapeutics, Inc. in?
Atrium Therapeutics, Inc. (RNA) operates in the Pharmaceutical Preparations industry.
What is RNA's market cap?
Atrium Therapeutics, Inc. (RNA) has a market capitalization of $230.08M as of 2026-06-30.
What exchange does RNA trade on?
Atrium Therapeutics, Inc. (RNA) trades on the Nasdaq.
Where is Atrium Therapeutics, Inc. incorporated?
Atrium Therapeutics, Inc. is incorporated in DE.